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Abstract
Acute mountain sickness (AMS) is a common problem among visitors at high altitude, and may progress to life-threatening
pulmonary and cerebral oedema in a minority of cases. International consensus defines AMS as a constellation of subjective,
non-specific symptoms. Specifically, headache, sleep disturbance, fatigue and dizziness are given equal diagnostic
weighting. Different pathophysiological mechanisms are now thought to underlie headache and sleep disturbance during
acute exposure to high altitude. Hence, these symptoms may not belong together as a single syndrome. Using a novel
visual analogue scale (VAS), we sought to undertake a systematic exploration of the symptomatology of AMS using an
unbiased, data-driven approach originally designed for analysis of gene expression. Symptom scores were collected from
292 subjects during 1110 subject-days at altitudes between 3650 m and 5200 m on Apex expeditions to Bolivia and
Kilimanjaro. Three distinct patterns of symptoms were consistently identified. Although fatigue is a ubiquitous finding, sleep
disturbance and headache are each commonly reported without the other. The commonest pattern of symptoms was sleep
disturbance and fatigue, with little or no headache. In subjects reporting severe headache, 40% did not report sleep
disturbance. Sleep disturbance correlates poorly with other symptoms of AMS (Mean Spearman correlation 0.25). These
results challenge the accepted paradigm that AMS is a single disease process and describe at least two distinct syndromes
following acute ascent to high altitude. This approach to analysing symptom patterns has potential utility in other clinical
syndromes.
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Introduction
Acute mountain sickness (AMS) occurs in up to 50% of
individuals ascending to high altitude [1] and may progress to life-
threatening pulmonary and cerebral oedema in a minority of cases
[2]. The present international consensus defines AMS as a
collection of subjective, non-specific symptoms [3]. Specifically,
headache, sleep disturbance, and vague symptoms of fatigue and
dizziness are given equal diagnostic weighting. Since we lack a
common underlying mechanism to explain these symptoms, it is
far from certain that they belong together as a single syndrome.
The most frequently-used criteria for the definition of AMS are
based on the self-reported Lake Louise consensus scoring system
(LLS) [3]. A positive Lake Louise Score can describe a spectrum of
non-specific symptoms experienced on exposure to high altitude,
and these may encompass more than one disease phenotype [4].
Headache is the cardinal feature of the LLS and is required
under the present criteria for diagnosis of AMS [3]. There is
evidence to suggest that the development of mild vasogenic
cerebral oedema leading to increased intracranial pressure may be
an important factor in the development of high altitude headache
and AMS [5]. Optic nerve sheath diameter, an indirect measure of
intracranial pressure, increases with altitude and also correlates
with AMS score [6,7]. Several small case series in which
participants were subjected to simulated high altitude before
undergoing cerebral MRI also demonstrated an increase in brain
volume [5,8]. A related hypothesis proposes that fluid redistribu-
tion to the intracellular space leading to astrocytic swelling
underlies the development of symptomatic AMS [9]. More
recently, it has been suggested that high altitude headache may
relate to restricted venous drainage following the hypoxia-
associated increase in cerebral blood flow at altitude [10].
In contrast, sleep disturbance at high altitude may be a
mechanistically separate problem. Changes in the control of
ventilation following acute ascent to altitude lead to a cyclical
respiratory pattern. The hypoxic ventilatory drive causes hypo-
capnia and a reduction in respiratory drive [11]. During sleep, in
the absence of the wakefulness drive to breathing, hypoventilation
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results in cyclical hypoxia and recurrent interruption of deep sleep
stages [12].
As a categorical score, LLS is inherently disadvantaged in any
attempt to quantify a continuous spectrum of disease severity. A
further problem in the measurement of AMS is that LLS scores at
high altitude produce a strongly skewed dataset, reducing the
power of statistical analyses and making it difficult to quantitatively
compare different symptoms, or to infer relationships between
severity and other physiological or biochemical measurements.
A visual analogue scale (VAS) comprises a continuous
horizontal line, each end of which is labelled by opposing
statements (e.g. ‘‘no pain at all’’ and ‘‘unbearable pain’’). Subjects
specify the severity of a symptom by marking the line at a point
between these two symptoms. This is then quantified by measuring
the position of the marked point (in mm) on the line. Visual
analogue scales have been rigorously validated as tools to quantify
the severity of subjective symptoms, particularly in pain medicine
[13–16], and are increasingly accepted for symptom scoring at
altitude [17]. Harris et al. used VAS scores as an endpoint in a
randomised controlled trial comparing treatments of high altitude
headache [18]. Since then, there have been four studies exploring
the relationship between VAS and LLS describing altitude
symptomatology [19–22], consistently demonstrating a correlation
between LLS and VAS, both for individual components of LLS
and overall LLS score. However, both the linearity of the
relationship and the threshold VAS measurement for diagnosis
of AMS are poorly defined. Unlike LLS, which is a standardised
score and comparable across different studies, VAS studies have
used different scores and as yet there is no consensus VAS for
altitude illness.
We sought to perform an unbiased quantitative assessment of
the symptomatology of AMS in healthy lowlanders acutely
exposed to high altitude. We used a novel VAS questionnaire to
record subjective symptoms experienced by research subjects over
the course of 1110 subject-days at high altitude. Here we report
the comparison between VAS and LLS, and apply a hypothesis-
free clustering methodology widely used in transcriptomics [23] to
identify different patterns of symptoms in individuals acutely
exposed to high altitude.
Materials and Methods
Ethics Statement
The work reported here was approved by the Lothian Research
Ethics Committee and the Tanzanian Institute for Medical
Research. Written informed consent was obtained from all
participants. The trial of antioxidant supplementation from which
this study drew some data was registered at clinicaltrials.gov
(NCT00664001).
Study Population
Data were collected from subjects at high altitude during two
research expeditions. One hundred and three participants were
recruited from the Apex 2 expedition to the Bolivian Andes [24–
26]. Subjects flew to La Paz, Bolivia (3650 m) and after 4–5 days’
acclimatisation ascended over a period of 90 minutes to 5200 m
by off-road vehicle. Forty one subjects were randomised to receive
antioxidant supplements (1 g L-ascorbic acid, 400 IU alpha-
tocopherol acetate, and 600 mg alpha-lipoic acid/day in four
divided doses starting five days before ascent to 5200 m), 20
subjects were randomised to receive sildenafil (150 mg daily in
three divided doses) and the remaining 42 received placebo only.
No subjects on the Apex 2 expedition took either acetazolamide or
non-steroidal anti-inflammatory drugs (NSAIDs). Data were also
included from 189 trekkers ascending to the Kibo Hut at 4730 m
on Mt Kilimanjaro in Tanzania, as described elsewhere [27]. Of
189 subjects, 149 were attempting to summit via the standard
Marangu route, which involves sleeping at huts located at 2743 m,
3760 m and 4730 m on the 5895 m summit attempt. Of these, 82
climbers had taken an additional rest day at 3760 m. The
remaining 40 subjects were completing the Rongai route with no
fixed sleeping points. These climbers were opportunistically
sampled on the mountain, and as such we had no control over
the medications used by the Kilimanjaro subjects.
Measurement of symptoms
Subjects were asked to complete a novel seven-question visual
analogue scale (VAS) questionnaire during acute exposure to high
altitude (conceived and designed by DJC, and provided in the
Figure S1). This assesses five symptoms associated with high
altitude: headache (‘‘no headache at all’’ to ‘‘worst headache
ever’’), nausea (1. ‘‘I really want to be sick’’ to ‘‘don’t feel sick at
all’’; 2.‘‘my guts are really bad’’ to ‘‘my guts are fine’’), fatigue (1.
‘‘I’m totally exhausted’’ to ‘‘I’m full of energy’’; 2. ‘‘I’m at my best’’
to ‘‘I’m at my worst’’), dizziness (‘‘no dizziness at all’’ to ‘‘more
dizzy than ever’’) and sleep quality (‘‘worst night’s sleep ever’’ to
‘‘best night’s sleep ever’’). Subjects were asked to mark their
symptoms on a spectrum between the two extreme statements by
marking their position on a horizontal 100 mm line. The direction
of the scales (whether the direction from left-to-right corresponded
to increasing or decreasing symptom severity) was deliberately
reversed for some questions, but remained constant for each
individual question over the course of the study. Questions were
scored by measuring the distance from the low symptom severity
end of the line, such that 0 mm corresponded to minimal severity
and 100 mm to maximal severity for all seven questions. Summing
the seven components produced a maximum total VAS score of
700 mm. The VAS included a quality control question, which
asked with different wording about symptoms of fatigue in order to
detect inattentive subjects. A minimum agreement of 40 mm was
required between the responses to two questions (‘‘I’m totally
exhausted’’ to ‘‘I’m full of energy’’, and ‘‘I’m at my best’’ to ‘‘I’m
at my worst’’).
Subjects also completed the Lake Louise Score (LLS) question-
naire, which includes assessment of headache, nausea and
vomiting, fatigue/weakness, dizziness and sleep quality. Partici-
pants score the severity of each symptom from 0 (no symptom) to
three (maximal severity); a total score of greater than or equal to
three with the presence of headache equates to acute mountain
sickness [3].
Sequential LLS and VAS data were collected daily from each of
the 103 Apex 2 subjects over 11 days of exposure to high altitude
(4 days at 3600 m, 7 days at 5200 m). Cross-sectional data from
the 189 Kilimanjaro subjects were recorded at 4730 m during
their ascent.
Data Analysis
VAS scores were measured by hand in mm. Groups of VAS
questionnaires exhibiting similar symptom profiles were identified
using a network analysis tool, BioLayout Express 3D, http://www.
biolayout.org/ [28]. This software is primarily used to visualize
and cluster networks from microarray expression data, in which
the Pearson correlation co-efficient is used as a measure of
similarity between gene expression profiles to generate a network
[29]. We created an undirected network, in which each node
(depicted by coloured spheres in figures) represented one VAS
questionnaire. Weighted edges (interconnecting lines) between
these nodes represent Pearson correlation coefficients (r) between
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the symptoms in each questionnaire above a threshold of r = 0.95.
This threshold is one of two arbitrary settings that have an impact
on the network characteristics, the other being the MCL inflation
value (MCLi, see below). In order to enable others to fully explore
this dataset, we have made the full dataset available for download
from http://www.altitude.org/ams.php.
A high correlation threshold of 0.95 was chosen in order to
restrict the network analysis to relationships between very similar
VAS questionnaires. VAS questionnaires with no connections
above this correlation threshold are removed from the network.
The MCL algorithm was used to subdivide the network into
discrete clusters of VAS questionnaires sharing similar features
[30]. MCL provides a data-driven method to group similar VAS
questionnaires with minimal input from the user, and hence
minimal opportunity for unconsciously introducing bias. It is
widely used for a variety of network clustering purposes, including
the detection of protein families from similarity graphs [31], and
inference of functional modules from protein-protein interactions
[32] and gene expression data [29].
The MCL algorithm is described in considerable detail
elsewhere, and we refer interested readers to the MCL website
(http://micans.org/mcl) and the validation paper for further
information [30]. Briefly, the algorithm simulates stochastic flow
through the network, iteratively enhancing flow to well-connected
nodes at the expense of poorly-connected nodes, until a stable state
occurs in which inherent network structure is revealed. The
granularity of the network (i.e. the size of individual clusters) is
determined by the inflation value (MCLi), which was set for this
analysis at 1.4.
The relationship between symptoms was explored by generating
a correlation matrix in GraphPad Prism (version 6.01, GraphPad
Software, CA) between VAS scores for each of five symptoms, and
in Biolayout Express 3D. The correlation between VAS and LLS
was explored using Spearman’s rank co-efficient, calculated in R
2.13.1 (R Foundation for Statistical Computing, Vienna, 2011)
[33].
A simple graphical interface was developed (Excel 2003,
Microsoft Corp, Redmond, WA), to allow exploration of the
effects of changing the weighting given to each symptom recorded
on the VAS score, the degree of concordance required between
the to quality control questions and the effects of square-root
normalization on the LLS and VAS data. The full dataset and
formulae for data manipulation are provided as supplementary
information at www.altitude.org/ams.php
Results
Visual analogue scale (VAS) and Lake Louise Score (LLS) data
were collected from 292 individuals over the course of 1110
subject-days at high altitude. This included 189 questionnaires
from 189 subjects at the Kibo Hut (4730 m) on Mt Kilimanjaro
and 921 questionnaires from 103 subjects on the Apex 2
expedition. From a possible 1133 subject-days on the Apex 2
expedition, data from 105 subject-days were lost as corresponding
VAS and LLS were not available. Twenty-five subjects from Apex
2 were evacuated from 5200 m with severe acute mountain
sickness. Questionnaires from these subjects were included only
until time of evacuation resulting in the loss of 107 subject days.
Sixty-five questionnaires (13 from Kilimanjaro, 52 from Apex 2,
5.9% of total questionnaires) were excluded as they did not meet
the minimum agreement threshold of 40 mm between the two
quality control questions on the VAS questionnaire. This left a
total of 1045 subject-days at altitude (176 at Kilimanjaro, 869 on
Apex 2), with both corresponding VAS and LLS data.
Figure 1. Identification of VAS questionnaires exhibiting similar symptom profiles using Biolayout Express 3D. Each node (coloured
sphere) represents a VAS questionnaire. Nodes are connected by weighted lines, which represent correlations between similar symptom profiles.
Nodes are connected with each other if the Pearson correlation coefficient between them exceeds 0.95. The MCL clustering algorithm (inflation= 1.4)
sub-divided this network into three discrete clusters of VAS questionnaires, each of which shared similar features. Figures adjacent to the clusters
represent the median VAS scores for each question in the VAS questionnaire. The green cluster (cluster 1) contains 407 nodes and corresponds to
subjects who slept poorly, and were fatigued but had little headache. The brown cluster (cluster 2) contains 127 nodes and corresponds to subjects
who slept poorly and did have headache. The purple cluster (cluster 3) contains 43 nodes and corresponds to subjects who had little sleep
disturbance but had headache. The remaining nodes do not correlate sufficiently with each other to form a significant cluster.
doi:10.1371/journal.pone.0081229.g001
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Cluster Analysis of AMS Symptoms
In order to maximise the power to detect different patterns of
associated symptoms, we chose a composite analysis, including all
questionnaires from within 1 week of a recent increase in altitude.
This combined data from disparate sources, with differences in
mode and rate of ascent, geographical location and drug
treatment, and includes several questionnaires from the same
volunteers at different times. The patterns reported here are
consistently replicated in subsets of volunteers with same location
and ascent rate, from the placebo group only and including only
one questionnaire for each volunteer (Figure S2).
In order to explore different patterns of related symptoms, VAS
data for the 1045 subjects-days at altitude were analysed in
BioLayout Express 3D. The network generated was clustered
using the MCL clustering algorithm (inflation value 1.4, minimum
cluster size 30 nodes) producing three main clusters (Figure 1). The
largest cluster contained 407 questionnaires, and corresponded to
subjects who slept poorly, were fatigued, but had minimal
headache or other symptoms. The second cluster of 127
questionnaires, contained subjects who reported poor sleep,
headache, and fatigue. The third cluster contained 43 question-
naires and corresponded to subjects who had little sleep
disturbance, but had headache and fatigue. The remaining
questionnaires did not form a cluster large enough to be included
in the analysis – the full dataset may be explored at www.altitude.
org/ams.php.
Symptom Correlation
The relationship between different symptoms (rather than
symptom profiles) was also investigated using the correlation
between two symptoms across the whole population of responses
from the Kilimanjaro expedition and the responses from Day 3 of
the Apex expedition. There were no multiple measures taken from
individual subjects. Symptoms recorded by the visual analogue
scale inter-correlated as shown in Table 1. Sleep was most weakly
correlated with the five other symptoms (mean correlation co-
efficient 0.25), whereas dizziness was most strongly correlated with
the other reported symptoms (mean correlation co-efficient
0.44)(Figure 2).
There was no significant difference between clusters in the
proportion of VAS responses from each of the Apex 2 treatment
groups (placebo [n=42], antioxidant [n=41], sildenafil [n=20]).
These data are shown in Table 2. Similarly, no relationship was
seen between age or sex and any pattern of symptoms (Figure S3).
Timing of sleep assessment
For practical reasons, AMS questionnaires inquire about sleep
quality on the night preceding the questionnaire. This is one reason
why AMS scores are lower on the first day following acute ascent.
However in physiological terms it is equally logical to assess sleep
on the following night. This is particularly important when assessing
the correlation of sleep with other symptoms, because the better
sleep quality experienced on the night before ascent will cause an
artefactual dissociation between sleep quality and the other
symptoms of AMS.
Our dataset enables us to address the effect of this change. We
repeated the correlation analyses on a subset of questionnaires in
which we substituted the sleep score from the following day. For
both the clustering of questionnaires with similar patterns of
symptoms (Figure S2), and the correlation between the 5
symptoms across all volunteers, the patterns described above were
consistently replicated.
Quantification of severity
Three hundred and eighty four of the 1045 questionnaires were
consistent with a diagnosis of acute mountain sickness using the
Lake Louise Score (LLS.2 with LLS headache.0). One subject
developed high altitude pulmonary edema (HAPE) at 3600 m;
there were no cases of HACE (high altitude cerebral edema). The
median of all LLS scores was 2 (interquartile range 1–4). The
mean total VAS was 192.6 mm with a standard deviation of
124.3 mm.
A square-root transformation resulted in normalisation of the
VAS data (Kolmogorov-Smirnov test: KS distance 0.02036, P.
0.10) but not the LLS data (Kolmogorov-Smirnov test: KS
distance 0.1620, P,0.0001) (Figure 3).
Discussion and Conclusion
The scale of the dataset collated here, collected during 1110
subject-days at altitude, enables for the first time a comprehensive
Table 1. Spearman correlation coefficients (95% confidence intervals) between VAS scores for the different symptom components
of the LLS.
Sleep GI upset Dizziness Headache Fatigue
Sleep x 0.23 (0.11–0.34) 0.20 (0.08–0.32) 0.25 (0.13–0.36) 0.30 (0.18–0.41)
GI upset x 0.58 (0.49–0.65) 0.43 (0.33–0.53) 0.44 (0.33–0.53)
Dizziness x 0.57 (0.48–0.65) 0.40 (0.29–0.50)
Headache x 0.38 (0.27–0.48)
Mean 0.25 (0.18–0.31) 0.42 (0.18–0.64) 0.44 (0.16–0.72) 0.41 (0.20–0.62) 0.38 (0.29–0.47)
Repeat measures (for GI upset and fatigue) were averaged. Colours transition from red through to green with increasing values of the Spearman correlation coefficient.
This analysis includes one questionnaire per subject (Apex 2 subjects on day 3 and all Kilimanjaro subjects).
doi:10.1371/journal.pone.0081229.t001
Figure 2. Correlations between different LLS symptoms. The
correlations between symptoms included in the Lake Louise Score was
explored across the whole population of responses (n = 1045) using
Biolayout 3D (minimum Pearson correlation cut–off r = 0.4). Headache,
fatigue, nausea and dizziness all correlate with each other, whereas
sleep is an outlier and correlates only with fatigue at this threshold.
doi:10.1371/journal.pone.0081229.g002
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quantitative analysis of symptom correlation in altitude illness. We
show that sleep disturbance is an outlier, correlating poorly with
other symptoms of AMS. By identifying clusters sharing common
patterns of symptoms, we demonstrate that distinct patterns of
disease are primarily characterised by the presence of sleep
disturbance or headache.
Among symptomatic individuals following acute ascent to high
altitude, some degree of fatigue was a ubiquitous finding. In
contrast, sleep disturbance and headache are each commonly
reported without the other. This is consistent with the hypothesis
that distinct pathogenetic mechanisms underlie sleep disturbance
and headache at high altitude.
Analysis of correlation networks is a standard tool for drawing
biological meaning from transcriptomic data [23,34,35]. As we
demonstrate here, the same approach may also have substantial
utility in classifying disease phenotypes. By providing an unbiased
allocation of subjects with similar symptoms into clusters, it
provides a novel and informative method for identifying patterns
of disease. This method may easily be extended to other
syndromes.
Our primary dataset contains repeated measures (1110 ques-
tionnaires obtained from 292 subjects), which may lead to a
learning bias in subjects completing the VAS [21]. We also used
symptom scores from some subjects who were taking oral
antioxidant supplements or sildenafil for other trials. However
these limitations do not affect the main outcomes. Repeat analyses
Table 2. The proportion of VAS responses from each
treatment group in each of the symptom clusters.
Cluster 1
(n=407)
Cluster 2
(n=127)
Cluster
3 (n =43)
Placebo (%) 130 (37.8%) 47 (40.9%) 17 (41.5%)
Antioxidant (%) 157 (45.6%) 38 (33.0%) 17 (41.5%)
Sildenafil (%) 57 (16.6%) 30 (26.1%) 7 (17.1%)
These differences are not statistically significant (Chi-squared test).
doi:10.1371/journal.pone.0081229.t002
Figure 3. Frequency distribution of LLS and VAS scores (n=1045). (A) Distribution of LLS. A positive LLS, indicating AMS, is a score of 3 or
greater in the presence of headache; (B) Distribution of Lake Louise Scores following square-root transformation; (C) Distribution of total VAS scores
(minimum 0 mm; maximum 700 mm); (D) Distribution of total VAS scores following square-root transformation of data. LLS: Lake Louise Score; VAS:
visual analogue scale; AMS: acute mountain sickness.
doi:10.1371/journal.pone.0081229.g003
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focussing only on a single time point, or removing subjects on
active drug treatments, did not affect the results and in these
supplementary analyses the pattern of clustering was maintained
(Figure S2).
Our study makes use of the largest VAS dataset to date to
explore altitude-associated symptomatology, with 292 subjects and
1110 subject-days at altitude. As expected, there is a strong
correlation between VAS and LLS [19–22]. Our work extends
previous attempts to evaluate VAS scores by demonstrating the
utility of VAS in creating a normally-distributed, continuous
measure of AMS. VAS have a high test-retest reliability and inter-
rater reliability [17] and may be more sensitive than discrete
measures [36]. In future research using VAS as an endpoint or
covariate, improved statistical power may be expected from the
use of parametric tests that may only be applied to normally-
distributed, continuous variables.
Furthermore, combining distinct pathophysiological processes
into a single summary measure carries a risk of introducing
excessive noise into studies of the pathogenesis of AMS, and of
reducing the magnitude of effect signals in therapeutic studies.
Focussing only on a group of well-correlated symptoms that share
common mechanisms will further improve the quality of future
research into AMS.
To be useful for clinical and physiological studies, a symptom
score must accurately reflect the severity of a single clinical entity
[37]. It is therefore critical that all of the symptoms included share
an underlying pathogenesis. If not, effective treatments will be
falsely rejected, and attempts to understand disease processes will
be obstructed. It is our view that the results presented here should
provoke a reassessment of consensus diagnostic criteria and
severity measures for AMS.
Supporting Information
Figure S1 VAS questionnaire form. Questionnaire given to
subjects to record VAS scores relating to symptoms experienced at
altitude on the Apex 2 expedition. The same form was used by
participants on the Kilimanjaro expedition.
(TIF)
Figure S2 Supplementary symptom networks. The net-
work graph created in Biolayout 3D Express, which incorporated
data from all 1045 questionnaires and is displayed as Figure 1, was
reproduced using differing questionnaire inclusion criteria. These
all produced at least two distinct clusters when clustered using a
MCL inflation value of 1.4. (A) includes questionnaires from Apex
2 Expedition subjects only (n = 869); (B) includes only question-
naires from subjects not taking either sildenafil or antioxidant
supplementation (n= 523); (C) includes questionnaires from
Kilimanjaro subjects only (n = 176); (D) includes only question-
naires from subjects at a single time point (day 3 of the Apex 2
expedition, and all Kilimanjaro participants, n = 269). (E) includes
Apex 2 questionnaires, in which the sleep score from the following
night was used in place of that from the preceding night (n = 625).
(TIFF)
Figure S3 Age and sex distribution in symptom net-
work. Each node (coloured sphere) represents a VAS question-
naire, connected by weighted lines, which represent correlations
between similar symptom profiles. Nodes are connected with each
other if the Pearson correlation coefficient between them exceeds
0.95. (A) Sex distribution of nodes, with questionnaires completed
by males denoted by green nodes, those by females by blue, and
missing demographic data by grey nodes; (B) Age distributions of
nodes, with questionnaires completed by under 21 year olds
represented by orange nodes, 22–25 year olds by pink nodes, and
those completed by over 26 years old by cyan. Missing data are
represented by grey nodes.
(TIFF)
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